Brief: OncoTherapy Science says first-patient enrollment in Phase I/II clinical study of OTS167
15/07/2016 08:33
July 15 (Reuters) - OncoTherapy Science Inc 4564.T :
* Says the first patient has been enrolled in Phase I/II
clinical study of OTS167, an MELK-specific inhibitor, for Acute
Myeloid Leukemia
Source text in Japanese: https://goo.gl/qgkfL9
Further company Coverage: 4564.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: qiujing.li.thomsonreuters.com@reuters.net))